Genta Incorporated,Biopharmaceutical company,Genasense® (oblimersen sodium) injection,Oncology,Bcl-2

Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s drugs include Ganite^® (gallium nitrate injection), Genasense^® (oblimersen sodium) injection, tesetaxel, and oral gallium. Genta is committed to developing innovative products to better the lives of people with cancer. Learn More

Leadership in Cancer Drug Development

Genta's team has extensive drug development and commercialization experience.

Oncology Focused Pipeline

Genasense^® (oblimersen sodium) Injection inhibits the production of a protein known as Bcl-2.

Click to view the Bcl-2 Mechanism of Action Video

News Highlights
Events

June 11, 2010
Genta Incorporated Announces Webcast of 2010 Annual Shareholders Meeting
Read More
June 7, 2010
Tesetaxel Results from Two Clinical Dose-Ranging Trials Presented at ASCO
Read More
June 6, 2010
Pooled Results of Early Endpoints from Phase 3 Trials of Genasense^® in Advanced Melanoma Presented at ASCO
Read More
May 13, 2010
Genta Incorporated Announces First Quarter 2010 Financial Results
Read More

VIEW ALL NEWS

12th Annual BIO CEO & Investor Conference

2010-02-08
New York, NY

3rd Oligonucleotide-based Therapeutics Conference

2010-03-23
Bethesda, MD

Genta Incorporated Reports Fourth Quarter and 2009 Year-End Financial Results

2010-03-29
Berkeley Heights, NJ

AACR (American Association for Cancer Research) 10^th annual meeting

2010-04-17
Washington, DC

2010 BIO International Convention Business Forum

2010-05-04
Chicago, IL

Genta Incorporated to Host Conference Call to Discuss First Quarter 2010 Highlights and Financial Results

2010-05-13
Berkeley Heights, NJ

2010 Annual Shareholders Meeting

2010-06-15
Morristown, NJ

VIEW ALL EVENTS